Senior Specialist, Biosamples
About this role
Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Summary
Tango Therapeutics has an exciting new opportunity for a Senior Specialist, Biosamples to join the Companion Diagnostics and Clinical Biomarkers Team and support multiple clinical trials. This is a matrixed role relying on partnerships with internal stakeholders and external collaborators, biorepositories, laboratories, and contract research organizations (CROs). Working collaboratively across functions, you will ensure implementation, compliance, and support of clinical biosample plans and management for early phase and late-stage trials in Tango’s clinical portfolio.
Your Role:
- Accountable for tracking, coordinating and overseeing all operational activities required to manage the lifecycle of clinical biosamples, ensuring sample integrity and GCP compliance throughout the process.
- Oversee shipment and receipt of clinical biosamples, document chain of custody throughout all stages of the clinical workflow and respond to issues as needed to ensure biosample custody is protected.
- Coordinate with internal and external stakeholders to manage the timely shipment of clinical samples, leveraging sample forecasts and inventory availability to support study milestones and laboratory testing needs.
- Manage relationships with laboratory and clinical study personnel internally and at external clinical sites, contract laboratories, and contract research organizations (CROs).
- Oversee compilation, quality control, and integration of cumulative inventory reports from external laboratories into Tango’s internal LIMS database.
- Conduct periodic audits of biosample inventory for each clinical program, and prepare audit summaries for relevant stakeholders.
- Independently collaborate with internal and external stakeholders to rapidly address biosample queries and facilitate data discrepancy resolution, as needed.
- Maintain effective verbal and written communication internally and with external collaborators and vendors.
- Ensure compliance and proper documentation in accordance with work instructions, SOPs, and all applicable regulations.
What You Bring:
- Minimum of a Bachelor’s degree in a life science concentration
- 3+ years clinical research experience
- Biotech or pharmaceutical sponsor experience highly preferred
- Experience working with contract research organizations (CROs), central laboratories and third party clinical laboratories
- Demonstrated familiarity with LIMS databases and other biosample tracking tools and systems
- Solid understanding of good clinical practice (GCP/ICH) and good clinical laboratory practice (GCLP)
- Strong communication, impeccable attention to detail, and outstanding follow-through
- Ability to learn independently on the job in a face paced environment
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Company at a glance
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents.
Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion.
What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity.
Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
Tired of cold applications?
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
Know someone who'd be great for this?